-
RBC Capital Upgrades Proteostasis Therapeutics (PTI) to Outperform Following 'Impressive Ph.II CF Doublet Data'
-
UPDATE: RBC Capital Downgrades Proteostasis Therapeutics (PTI) to Sector Perform on Mixed '801 Data
-
Proteostasis Therapeutics (PTI) Announces 9M Share Common Offering
-
Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock
-
Pre-Open Movers 03/09: (PDLI) (ACRX) (ECYT) Higher; (AUTO) (VNRX) (BIG) Lower (more...)
-
RBC Capital Starts Proteostasis Therapeutics (PTI) at Outperform
-
Proteostasis Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Proteostasis Therapeutics (PTI) Prices 8M Shares at $5
-
Proteostasis Therapeutics Prices Public Offering of Common Stock
-
Proteostasis Therapeutics (PTI) to Offer 7M Shares of Common Stock
-
Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock
-
Pre-Open Movers 12/12: (PTI) (RPRX) (GLYC) Higher; (PPHM) (MARA) (CASY) Lower (more...)
-
After-Hours Stock Movers 12/11: (PTI) (KMG) Higher; (PPHM) (CASY) (OAS) Lower (more...)
-
Proteostasis Therapeutics Announces Closing of Follow-On Public Offering of Common Stock
-
Proteostasis Therapeutics (PTI) Prices 5M Common Stock Offering at $13/Share
-
Proteostasis Therapeutics Announces Pricing of Public Offering of Common Stock
-
Notable Analyst Rating Changes 3/7: (GGP) (MT) (UDR) Upgraded; (MU) (SSYS) (IHG) Downgraded
-
RBC Capital Starts Proteostasis Therapeutics (PTI) at Outperform
-
Proteostasis Therapeutics, Inc. Announces Closing of Initial Public Offering
-
Proteostasis Therapeutics (PTI) IPO Opens Flat
-
Proteostasis Therapeutics (PTI) Prices Upsized IPO at $8, Well Below Plan
-
Proteostasis Therapeutics, Inc. Announces Pricing of Initial Public Offering
-
Proteostasis Therapeutics (PTI) Files $86.25M IPO

